title: Effects of levodopa oral bolus on the kinematics of the pointing movements in Parkinson's disease patients.
abstract: We studied the time-course of a levodopa oral bolus effects on the kinematics of patients affected by a mild akinetic-rigid form of idiopathic Parkinson's disease (PD). Eleven PD patients were evaluated: a) in OFF-state, that is before their first medication or after its withdrawal, b) in ON-state, that is at 1/2, 1, 2, 3, 4, 5, 6, 24, 30 and 48 hours after the administration of 250 mg of levodopa plus 25mg of carbidopa. The main kinematics (i. e.movement time, peak of velocity, peak of acceleration and peak of deceleration) of pointing movements to six target-stimuli placed on the horizontal plane of a table were recorded. Clinical conditions were assessed according to the Motor Examination section of the Unified Parkinson's Disease Rating Scale. The levopoda bolus had stable clinical effects only within the first six hours from its administration. The decline of the clinical response was marked by the changes of peak acceleration whereas other kinematics (i. e. movement time and the peak of velocity) changed also in the late observations (24, 30 and 48 hours after drug intake). The dissociation between the persistent improvement on movement time on peak velocity and the rapid deterioration of levodopa effects on early kinematics (i. e. peak acceleration) could be accounted for by a progressive decline in movement programming.
authors.affiliation: DiNOOP, Università degli Studi di Palermo, Via La Loggia, 1, 90129 Palermo, Italy. rcamarda@neuro.unipa.it
authors.forename: R
authors.initials: R
authors.lastname: Camarda
authors.forename: C
authors.initials: C
authors.lastname: Camarda
authors.forename: S
authors.initials: S
authors.lastname: Grimaldi
authors.forename: L K C
authors.initials: LK
authors.lastname: Camarda
authors.forename: R
authors.initials: R
authors.lastname: Monastero
authors.forename: M
authors.initials: M
authors.lastname: Gangitano
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage*; D001696:Biomechanical Phenomena; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D011597:Psychomotor Performance / Q000187:drug effects*; D013997:Time Factors
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa